cetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chimeric origin	4954	205923-56-4

Description:

Molecule	Description
Synonyms: cetuximab cetuximab (genetical recombination) erbitux C-225 IMC-C225	A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

cetuximab
cetuximab (genetical recombination)
erbitux
C-225
IMC-C225

A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Feb. 12, 2004	FDA	IMCLONE
July 16, 2008	PMDA	Merck
June 29, 2004	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	466.94	22.69	122	12454	4874	63471572
Diarrhoea	208.50	22.69	444	12132	714922	62761524
Mucosal inflammation	191.62	22.69	118	12458	46810	63429636
Neutropenia	186.28	22.69	200	12376	174805	63301641
Malignant neoplasm progression	176.07	22.69	139	12437	81982	63394464
Dehydration	168.63	22.69	189	12387	173165	63303281
Paronychia	145.76	22.69	51	12525	5514	63470932
Hypomagnesaemia	134.70	22.69	79	12497	28658	63447788
Skin toxicity	122.68	22.69	43	12533	4671	63471775
Disease progression	114.38	22.69	131	12445	122627	63353819

Showing 1 to 10 of 74 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	900.33	18.41	283	24659	5906	34926083
Infusion related reaction	439.44	18.41	337	24605	52720	34879269
Mucosal inflammation	423.86	18.41	291	24651	38331	34893658
Hypomagnesaemia	298.76	18.41	189	24753	21662	34910327
Rash	292.31	18.41	548	24394	222204	34709785
Skin toxicity	286.12	18.41	113	24829	4671	34927318
Anaphylactic reaction	284.43	18.41	213	24729	32088	34899901
Dehydration	266.17	18.41	391	24551	129578	34802411
Radiation skin injury	257.67	18.41	67	24875	678	34931311
Paronychia	234.07	18.41	89	24853	3316	34928673

Showing 1 to 10 of 137 entries

Previous1 2 3 4 5…14Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	1221.75	18.89	352	32323	9641	79702072
Mucosal inflammation	445.55	18.89	314	32361	75266	79636447
Hypomagnesaemia	421.72	18.89	254	32421	46657	79665056
Skin toxicity	395.11	18.89	143	32532	8171	79703542
Dehydration	351.70	18.89	469	32206	247718	79463995
Paronychia	351.34	18.89	129	32546	7679	79704034
Neutropenia	326.68	18.89	489	32186	287221	79424492
Malignant neoplasm progression	322.83	18.89	335	32340	135655	79576058
Radiation skin injury	303.98	18.89	78	32597	1356	79710357
Diarrhoea	263.31	18.89	873	31802	879616	78832097

Showing 1 to 10 of 172 entries

Previous1 2 3 4 5…18Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01FE01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA EPC	N0000175664	Epidermal Growth Factor Receptor Antagonist
FDA MoA	N0000020010	HER1 Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological

Showing 1 to 5 of 5 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Head and neck cancer	indication	255055008	DOID:11934
Squamous cell carcinoma of mouth	indication	307502000
Rectal cancer with wild-type RAS	indication	363351006	DOID:1993
Malignant tumor of colon	indication	363406005	DOID:219
Squamous cell carcinoma of larynx	indication	405822008
Squamous cell carcinoma of pharynx	indication	408649007
Squamous cell carcinoma of nose	indication	448930008

Showing 1 to 7 of 7 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	ANTIBODY BINDING	Kd	9.41		IUPHAR	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
008568	NDDF
17947	MMSL
318341	RXNORM
4021419	VUID
4021419	VANDF
409400001	SNOMEDCT_US
409401002	SNOMEDCT_US
48970	MMSL
6882	IUPHAR_LIGAND_ID
7906	INN_ID

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-948	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-948	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-958	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-958	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections

Showing 1 to 4 of 4 entries

Previous1Next